Home  Our Mission  Precision Medicine  Prosigna®  Clinical Research  Contact Us 

Risk assessment you
can count on...

What is Prosigna?

Prosigna is the only PAM50-based, early-stage breast cancer assay to deliver a highly accurate assessment of risk of distant recurrence with a personalized prognostic score that identifies your patient's 10-year risk.
Prosigna is based on the PAM50 gene signature:
  • Classifies tumours into 1 of 4 intrinsic substypes (Luminal A, Luminal B, HER2-enriched and Basal-like)
    • Intrinsic subtypes are biologically and clinically distinct types of breast cancer that help define tumour biology2-5
    • Provide valuable prognostic information to guide clinical decisions
    • According to the St. Gallen Guidelines, systemic therapy recommendations should follow intrinsic subtype classification4
  • Generates a Risk of Recurrence (ROR) score from a properietary algorithm based on PAM50 gene signature, intrinsic subtype, tumour size, nodal status and proliferation score
Prosigna is both CE-marked and FDA 510(k) cleared for FFPE breast tissue, also licensed and/or approved for use in North America, Europe, Canada and Australia

Which patients are appropriate for Prosigna?

Postmenopausal women with hormone receptor-positive, node negative (stage I or Stage II), or node-positive (Stage II and IIIA) breast cancer to be treated with adjuvant endocrine therapy.

Why choose Prosigna?

Prosigna provides a risk catergory and numerical score for assessment of the risk of distant recurrence of disease at 10 years, helping to inform clinical decisions with prognostic information beyond standard clinical variables (age, grade, tumour size, nodal status, and adjuvant therapy).

  • Validated on 2,479 samples in the combined ABCSG-8 and TransATAC studies.
  • The test is FDA 510(k) cleared and CE-marked.
  • Recognized and listed in multiple international guidelines including ASCO, NCCN, and ESMO.

Please contact us for further information and/or test ordering.

Reference: 1. Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc., 2013. 2. Perou CM et al., Nature 2000; 406(6797); 747-752. 3. Sorlie T et al. Proc Nati Acad Sci USA, 2003; 100(14):8418-23. 4. Goldhirsch A et al. Ann Oncol, 2013;24:2206-2223. 5. Cancer Genome Atlas Network. Nature 2012;290(7418):61-70. 6. Creighton CJ. Biologics. 2012;6:289-297. 7. Parjer JS et al. J Clin Oncol. 2009;27(8): 1160-1167. 8. Dowsett M et al. J Clin Oncol.. 2013;31(22):2783-2790. 9. Gnant M et al. Ann Oncol. 2004;25(2):339-45. 10. Voduc KD et al. J Cllin Oncol. 2010;28(10):1684-91. 11. Haque R et al. Cancer Epidermiol Biomarkers Prev. 2012;21(10):1848-1855.